NR3C2 and diabetic kidney disease: Despite therapeutic advances, including the use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 agonists, and non‐steroidal mineralocorticoid receptor antagonists, managing DKD remains challenging.